About Jiuhua

About Jiuhua

ABOUT JIUHUA

development process

2022

Ⅰ. Won the title of "Top Ten Enterprises" in Langya District, Chuzhou City in 2021

Ⅱ. Jiuhua&huayuan has been selected as the top strength and high-quality development achievement enterprise of Chinese Medicine

Ⅲ. Ranked among the top 20 leading enterprises in agricultural industrialization in 2022

Ⅳ. Shortlisted as the top 100 Chinese traditional medicine enterprises in 2021

Ⅴ. Baimeixing ® Bairui granule was listed in the "Chinese medicine brand list"

2021

Ⅰ. The company won the title of "2020 Law-abiding and Integrity Enterprise in China's Pharmaceutical Industry"

Ⅱ. The company has won the list of "2020 Chinese National Pharmaceutical Excellent Brand Enterprises"

Ⅲ. The planting base of Pleurotus is identified as the "Top Ten Anhui Medicines" Industrial Demonstration Base

Ⅳ. The company entered the top 100 Chinese traditional medicine enterprises in 2020

Ⅴ.Bairui Granules and Yuye Jinhua Qingre Tablets appeared at the National "Thirteenth Five-Year" Science and Technology Innovation Achievement Exhibition

Ⅵ. Baimeixing® Bairui Granules entered the "2021 China Pharmaceutical Brand List"

2020

Ⅰ. The company was selected as the construction unit of the "Top Ten Anhui Medicines" industrial demonstration bases.

Ⅱ. The company was rated as "Provincial Key Leading Enterprise of Agricultural Industrialization".

Ⅲ. Ranked in the TOP100 list of Chinese traditional Chinese medicine enterprises in 2019!

2019

Ⅰ. The company was rated as "2018 Chuzhou Environmental Protection and Integrity Enterprise".

Ⅱ. Bairui Granules entered the new edition of "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2019 Edition)".

Ⅲ. Zhenyuan Tablet has entered the new version of the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2019 Edition)".

2018

Ⅰ. The company was recognized as a "high-tech enterprise" for the second time.

Ⅱ. The company was approved to set up "Anhui Postdoctoral Research Station".

Ⅲ. The company was rated as "the city's top ten industrial enterprises in 2017".

Ⅳ. Bairui Granules entered the new edition of "National Essential Medicines List (2018 Edition)".

2014

Bairui Granules entered the top ten Chinese patent medicines for heat-clearing and detoxification.

2015

Bairui granules (tablets) are listed in the Infectious Diseases of the Clinical Application Guidelines for Chinese Patent Medicines.

2017

Ⅰ. The company was rated as "2016 Excellent Industrial Enterprise of the City".

Ⅱ. The company was recognized as "Provincial Enterprise Technology Center".

Ⅲ. Bairui Granules entered the "National Basic Medical Insurance, Industrial Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)".

2016

Ⅰ. Won the 2015 Langya District Taxation "Top Ten" and "Top Ten" Enterprise Commendation.

Ⅱ. Become an innovative enterprise in Chuzhou City.

Ⅲ. Enpagliflozin products won the 2016 Major Science and Technology Project of Anhui Provincial Department of Science and Technology.

Ⅳ. The "Bomeixing" brand of Bairui preparation was awarded the recognition of famous trademark in Anhui Province.

2012

Ⅰ. Bairui Capsules (granules) were included in the "2012 Tianjin Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog".

Ⅱ. The project "Bairui Granules, the Millennium Heritage of Xin'an Medicine, Innovative Special Medicine for Children's Upper Respiratory Tract Infections" won the second prize of "Huaxia Healthcare International Promotion Science and Technology Award".

2011

Ⅰ. As a rare wild medicinal material, Pleurotus is listed as a key protected authentic medicinal material by the Anhui Provincial Government.

Ⅱ. Bairui Tablet was included in the List of Supplementary Drugs of Primary Medical Institutions in Shanghai.

2013

Bairui was shortlisted in the top 10 list of ENT drugs in Chinese hospitals in 2013.

2006

Bairui Tablets and Bairui Capsules obtained the National "Certificate of Protected Varieties of Traditional Chinese Medicine".

2007

Bairui tablets are listed as anti-infective botanicals in the "New Pharmacology" (16th edition), which is regarded as the authority of clinical medication by the majority of medical workers.

2009

Bairui Granules (sugar-free) was successfully launched, making an important contribution to the prevention and control of upper respiratory tract infections in children in China, and has become the main drug for the treatment of viral infections such as influenza and hand, foot and mouth disease.

2010

Ⅰ. Bairui's products have entered the "2010 Medical Insurance Drug List" in Shanghai, Jiangsu, Anhui, Hainan and other provinces.

Ⅱ. Bairui products are listed in the "Traditional Chinese Medicine Otolaryngology Clinical Diagnosis and Treatment
Guidelines" by the State Administration of Traditional Chinese Medicine.

1978

Bairui Tablets and Bairui Capsules were launched.

1999

It is listed in "Chinese Materia Medica", which represents the highest and latest level of contemporary Chinese medicine research in my country, compiled by the State Administration of Traditional Chinese Medicine.

1977

The herb is listed in the first part of the "Pharmacopoeia of the People's Republic of China".